VitaNova Life Sciences Corp financial data

Symbol
YJGJ on OTC
Location
New York, NY
Fiscal year end
30 April
Latest financial report
10-Q - Q3 2025 - 15 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 592% % -16%
Quick Ratio 18% %
Debt-to-equity 20% % 23%
Return On Equity 51% % 233%
Return On Assets 42% % 223%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25,012,270 shares 0%
Common Stock, Shares, Outstanding 25,012,270 shares 0%
Entity Public Float $0 USD
Common Stock, Value, Issued $25,012 USD 0%
Weighted Average Number of Shares Outstanding, Basic 25,012,270 shares 0%
Weighted Average Number of Shares Outstanding, Diluted 25,012,270 shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $2,792,524 USD 188%
Cost of Revenue $1,116,237 USD 206%
General and Administrative Expense $246,179 USD 63%
Operating Income (Loss) $1,257,858 USD 392%
Nonoperating Income (Expense) $120 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,255,793 USD 394%
Income Tax Expense (Benefit) $392,974 USD 282%
Net Income (Loss) Attributable to Parent $862,819 USD 470%
Earnings Per Share, Basic 0.03 USD/shares 200%
Earnings Per Share, Diluted 0.03 USD/shares 200%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current $882,612 USD 1430%
Inventory, Net $11,267 USD -96%
Other Assets, Current $3,441 USD 0%
Assets, Current $2,336,244 USD 86%
Assets $2,336,244 USD 86%
Accounts Payable, Current $168,450 USD
Accrued Liabilities, Current $68,713 USD
Liabilities, Current $438,051 USD 96%
Liabilities $438,051 USD 96%
Retained Earnings (Accumulated Deficit) $857,210 USD
Stockholders' Equity Attributable to Parent $1,898,193 USD 83%
Liabilities and Equity $2,336,244 USD 86%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $263,810 USD
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Common Stock, Shares Authorized 75,000,000 shares 0%
Common Stock, Shares, Issued 25,012,270 shares 0%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,259,281 USD 465%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Deferred Tax Assets, Valuation Allowance $45,318 USD 42%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross $147,929 USD 88%
Deferred Tax Assets, Operating Loss Carryforwards $102,611 USD 118%
Deferred Federal Income Tax Expense (Benefit) $0 USD
Additional Paid in Capital $1,012,971 USD 0%
Current State and Local Tax Expense (Benefit) $3,276 USD
Current Federal Tax Expense (Benefit) $10,585 USD 8%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Deferred State and Local Income Tax Expense (Benefit) $0 USD